MedTrace Logo

Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis Risk in Postmenopausal Females

NCT07365514 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 159

Last updated 2026-01-27

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the effects of blackcurrant (BC) supplementation on changes in bone density and gut microbiome composition in postmenopausal females.

Conditions

  • Postmenopausal Osteoporosis
  • Gut Microbiome
  • Menopause

Interventions

DRUG

Blackcurrant (BC) extract

Consume three capsules containing 1,176 mg BC of extract (392 mg BC per capsule)

DRUG

Placebo

Consume three placebo capsules (392 mg placebo per capsule)

DRUG

Blackcurrant (BC) extract

Consume three capsules per day containing 784 mg of blackcurrant (BC) extract (261.33 mg BC and 130.67 mg placebo per capsule)

Sponsors & Collaborators

  • University of Connecticut

    lead OTHER

Principal Investigators

  • Ock Chun, PhD · University of Connecticut

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-01
Primary Completion
2028-02-29
Completion
2029-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07365514 on ClinicalTrials.gov